+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma



Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma



Dermatology 190(3): 214-217



Background: Several neoplasms including cutaneous T-cell lymphomas, malignant melanoma and Kaposi's sarcoma have been successfully treated with systemic or intralesional interferons (IFNs). Recently, intralesional alpha-IFN has also been employed in the treatment of basal cell carcinoma (BCC). Objective: The aim of our study was to evaluate the efficacy of IFN alfa-2b in the treatment of BCC. Methods: 140 patients with BCC were treated with intra- and perilesional injections of recombinant IFN alfa-2b at a dosage of 1.5-3 times 10-6 IU, three times a week for 4-8 weeks. Results: Complete response was achieved in 94 patients (67.1%), partial response in 33 patients (23.6%) and no response in 13 patients (9.3%). Side effects included fever, headache, fatigue and nausea but were reversible with the use of paracetamol. None of the patients discontinued therapy due to side effects. After a mean follow-up period of 36 months (12-54 months) no relapse has been observed. Conclusion: Based on our results, intra- and perilesional IFN alfa-2b represents an effective, alternative treatment for BCC.

(PDF emailed within 0-6 h: $19.90)

Accession: 009702727

Download citation: RISBibTeXText

PMID: 7599384

DOI: 10.1159/000246688


Related references

Intralesional interferon alfa-2b in the treatment of basal cell carcinoma and squamous cell carcinoma Revisited. Journal of Investigative Dermatology 119(1): 349, July, 2002

Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma. Australasian Journal of Dermatology 35(2): 71-75, 1994

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 8(10): 1637-1649, 1990

Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b. Journal of Drugs in Dermatology 9(4): 381-384, 2010

Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b. Journal of the American Academy of Dermatology 31(1): 109-111, 1994

Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Journal of Dermatology 23(6): 394-396, 1996

Recombinant interferon alfa 2a rifn alfa a in patients with metastatic renal cell carcinoma. Blut 55(4): 363, 1987

Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. Journal of the American Academy of Dermatology 24(5 Pt 1): 731-734, 1991

Recombinant interferon gamma treatment of basal cell carcinoma. Clinical Research 39(2): 504A, 1991

Further experience with recombinant interferon alfa IFN-2b in metastatic renal cell carcinoma Analysis of 2 5 oligo synthetase and circulating interferon. Journal of Interferon Research 12(SUPPL 1): S160, 1992

Intralesional treatment of basal cell carcinoma with low-dose recombinant interferon gamma. Journal of the American Academy of Dermatology 21(4 Pt 1): 734-735, 1989

Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. Journal of Clinical Oncology 6(10): 1604-1610, 1988

Intralesional alfa-2a interferon therapy for basal cell carcinoma. Cancer Letters. 91(2): 215-219, 1995